跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

PHR1397

Supelco

氟轻松

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

氟轻松, 6α,9α-二氟-11β,16α,17α,21-四羟基-1,4-妊娠双烯-3,20-二酮, 6α,9α-二氟-16α-羟基泼尼松龙16,17-缩丙酮, 6α-氟代曲安奈德, 仙乃乐, 醋酸肤轻松

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C24H30F2O6
CAS号:
67-73-2
分子量:
452.49
EC 号:
200-668-5
MDL编号:
MFCD00010525
UNSPSC代码:
41116107
PubChem化学物质编号:
329823371
NACRES:
NA.24

等级

certified reference material
pharmaceutical secondary standard

质量水平

300

Agency

traceable to BP 160
traceable to Ph. Eur. F0200000
traceable to USP 1275009

API类

fluocinolone

CofA

current certificate can be downloaded

技术

HPLC: suitable
gas chromatography (GC): suitable

mp

267-269 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-30°C

SMILES字符串

CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO

InChI

1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

InChI key

FEBLZLNTKCEFIT-VSXGLTOVSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

Fluocinolone Acetonide is a soluble potent steroid, approved for implantable corticosteroid devices named fluocinolone acetonide intravitreal implants for the treatment of chronic uveitis.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

应用

Fluocinolone Acetonide may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using differential-pulse polarography.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

分析说明

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

其他说明

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

附注

To see an example of a Certificate of Analysis for this material enter LRAA2173 in the slot below. This is an example certificate only and may not be the lot that you receive.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H315,H319,H335

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number
LRAD6993
LRAD2344
LRAD3247
LRAC4076
LRAA9183

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Determination of fluocinolone acetonide in pharmaceutical preparations by differential-pulse polarography
Leung PC and Tam KYS
Analyst, 106(1258), 100-104 (1981)
The
Surgical management of inflammatory eye disease (2008)
The
Profiles of Drug Substances Excipients and Related Methodology Acute and Chronic Complications of Diabetes An Issue of Endocrinology and Metabolism Clinics E Book, 42(1258) (2013)
Wyatt B Messenger et al.
Drug design, development and therapy, 7, 425-434 (2013-06-06)
Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies
Elizabeth A Sugar et al.
Ophthalmology, 121(10), 1855-1862 (2014-06-09)
To evaluate the 3-year incremental cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for the treatment of noninfectious intermediate, posterior, and panuveitis. Randomized, controlled, clinical trial. Patients with active or recently active intermediate, posterior, or panuveitis enrolled in the Multicenter
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门